SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZ ...